Key points are not available for this paper at this time.
extensive experience in the treatment of cardiogenic shock and the application of various mechanical circulatory assist systems.All centres are characterized by a close interdisciplinary collaboration between the departments of cardiology and intensive care medicine, and.30day results on the primary and secondary endpoints of the first 150 patients are expected to be available in mid-2020. PerspectiveThe ACCOST-HH study is the first randomized multi-centre trial to provide a novel molecular therapeutic strategy for cardiogenic shock and its sequelae.As first-in-class therapy, the trial directly aims to target the deadly triad of cardiogenic shock myocardial cell death, inflammatory exacerbation, and loss of vascular integrity.The study has been developed in adaptive sample-size design.After the availability of 30day results in the first 150 patients the Phase 2 trial will be immediately transformed into a Phase 2/3 study in case a positive trend for mortality is observed in the Adrecizumab group, and recruitment will continue until the next interim analysis at a total of 300 patients.In case the antibody proves beneficial, this approach will allow the fastest possible implementation into clinical guidelines.
Spaccarotella et al. (Sun,) studied this question.